感染症診断の世界市場：洞察、競合情勢、市場予測：2030年

感染症診断の市場規模は、2023年のに385億2,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に3.80%のCAGRで拡大し、2030年には481億米ドルに達すると予測されています。感染症診断市場は、HIV、B型・C型肝炎、インフルエンザを含む感染症患者の増加、主要企業による革新的な新製品の投入などにより大きな成長を遂げており、これらが2024年から2030年までの予測期間中に感染症診断市場全体の成長に寄与する主要因として作用しています。

世界保健機関（WHO）の2024年の発表によると、2022年には世界で約3,900万人がHIV感染症に罹患していました。また、3,750万人近くが成人（15歳以上）であり、約150万人が15歳未満の小児であるとしています。感染症診断は、HIV感染を特定し、早期発見、治療モニタリング、感染の予防を可能にする上で極めて重要です。分子検査、抗原・抗体検査、ポイントオブケア検査などの技術は、HIVの診断、ウイルス量の評価、治療方針の決定に広く用いられています。

さらに、市場各社による革新的な新製品の投入が、同製品の市場シェアを押し上げています。例えば、2023年2月、Thermo Fisherはインドで感染症検出用のリアルタイムPCRキットを発表しました。Applied BiosystemsのTaqPath PCRキットは、多剤耐性結核（MDR-TB）、MTB、B型肝炎（HBV）、C型肝炎（HCV）、HIV、HLA-B27などの遺伝子分析などの診断開発・検査において信頼性を提供するように設計されています。

したがって、2024年から2030年までの予測期間中、上記のすべての要因が絡み合って感染症診断市場を牽引すると予測されています。

当レポートでは、世界の感染症診断市場について調査し、市場の概要とともに、タイプ別、技術別、技法別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 感染症診断市場レポートのイントロダクション

第2章 感染症診断市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 感染症診断市場の主な要因分析

• 感染症診断市場の促進要因
• 感染症診断市場の抑制要因と課題
• 感染症診断市場の機会

第6章 感染症診断市場のポーターのファイブフォース分析

第7章 感染症診断市場の評価

• タイプ別
• 技術別
• 技法別
• 用途別
• エンドユーザー別
• 地域別

第8章 感染症診断市場の企業と製品プロファイル

• BD
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Abbott
• bioMerieux SA
• QIAGEN
• DiaSorin S.p.A
• Meridian Bioscience, Inc.
• Quest Diagnostics
• Thermo Fisher Scientific Inc.
• Cepheid
• Siemens Healthcare GmbH
• Ortho Clinical Diagnostics
• Biocare Medical, LLC.
• Bruker
• Cardinal Health
• Chembio Diagnostics, Inc.
• Novacyt
• Trinity Biotech
• OJ-Bio Limited

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Infectious Disease Diagnostics Market in Global (2021-2030)
• Table 3: Infectious Disease Diagnostics Market in Global by Type (2021-2030)
• Table 4: Infectious Disease Diagnostics Market in Global by Technology (2021-2030)
• Table 5: Infectious Disease Diagnostics Market in Global by Technique (2021-2030)
• Table 6: Infectious Disease Diagnostics Market in Global by Application (2021-2030)
• Table 7: Infectious Disease Diagnostics Market in Global by End-User (2021-2030)
• Table 8: Infectious Disease Diagnostics Market in Global by Geography (2021-2030)
• Table 9: Infectious Disease Diagnostics Market in North America (2021-2030)
• Table 10: Infectious Disease Diagnostics Market in the United States (2021-2030)
• Table 11: Infectious Disease Diagnostics Market in Canada (2021-2030)
• Table 12: Infectious Disease Diagnostics Market in Mexico (2021-2030)
• Table 13: Infectious Disease Diagnostics Market in Europe (2021-2030)
• Table 14: Infectious Disease Diagnostics Market in France (2021-2030)
• Table 15: Infectious Disease Diagnostics Market in Germany (2021-2030)
• Table 16: Infectious Disease Diagnostics Market in United Kingdom (2021-2030)
• Table 17: Infectious Disease Diagnostics Market in Italy (2021-2030)
• Table 18: Infectious Disease Diagnostics Market in Spain (2021-2030)
• Table 19: Infectious Disease Diagnostics Market in the Rest of Europe (2021-2030)
• Table 20: Infectious Disease Diagnostics Market in Asia-Pacific (2021-2030)
• Table 21: Infectious Disease Diagnostics Market in China (2021-2030)
• Table 22: Infectious Disease Diagnostics Market in Japan (2021-2030)
• Table 23: Infectious Disease Diagnostics Market in India (2021-2030)
• Table 24: Infectious Disease Diagnostics Market in Australia (2021-2030)
• Table 25: Infectious Disease Diagnostics Market in South Korea (2021-2030)
• Table 26: Infectious Disease Diagnostics Market in Rest of Asia-Pacific (2021-2030)
• Table 27: Infectious Disease Diagnostics Market in the Rest of the World (2021-2030)
• Table 28: Infectious Disease Diagnostics Market in the Middle East (2021-2030)
• Table 29: Infectious Disease Diagnostics Market in Africa (2021-2030)
• Table 30: Infectious Disease Diagnostics Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Infectious Disease Diagnostics Market in Global (2021-2030)
• Figure 3: Infectious Disease Diagnostics Market in Global by Type (2021-2030)
• Figure 4: Infectious Disease Diagnostics Market in Global by Technology (2021-2030)
• Figure 5: Infectious Disease Diagnostics Market in Global by Technique (2021-2030)
• Figure 6: Infectious Disease Diagnostics Market in Global by Application (2021-2030)
• Figure 7: Infectious Disease Diagnostics Market in Global by End-User (2021-2030)
• Figure 8: Infectious Disease Diagnostics Market in Global by Geography (2021-2030)
• Figure 9: Infectious Disease Diagnostics Market in North America (2021-2030)
• Figure 10: Infectious Disease Diagnostics Market in the United States (2021-2030)
• Figure 11: Infectious Disease Diagnostics Market in Canada (2021-2030)
• Figure 12: Infectious Disease Diagnostics Market in Mexico (2021-2030)
• Figure 13: Infectious Disease Diagnostics Market in Europe (2021-2030)
• Figure 14: Infectious Disease Diagnostics Market in France (2021-2030)
• Figure 15: Infectious Disease Diagnostics Market in Germany (2021-2030)
• Figure 16: Infectious Disease Diagnostics Market in United Kingdom (2021-2030)
• Figure 17: Infectious Disease Diagnostics Market in Italy (2021-2030)
• Figure 18: Infectious Disease Diagnostics Market in Spain (2021-2030)
• Figure 19: Infectious Disease Diagnostics Market in the Rest of Europe (2021-2030)
• Figure 20: Infectious Disease Diagnostics Market in Asia-Pacific (2021-2030)
• Figure 21: Infectious Disease Diagnostics Market in China (2021-2030)
• Figure 22: Infectious Disease Diagnostics Market in Japan (2021-2030)
• Figure 23: Infectious Disease Diagnostics Market in India (2021-2030)
• Figure 24: Infectious Disease Diagnostics Market in Australia (2021-2030)
• Figure 25: Infectious Disease Diagnostics Market in South Korea (2021-2030)
• Figure 26: Infectious Disease Diagnostics Market in Rest of Asia-Pacific (2021-2030)
• Figure 27: Infectious Disease Diagnostics Market in the Rest of the World (2021-2030)
• Figure 28: Infectious Disease Diagnostics Market in the Middle East (2021-2030)
• Figure 29: Infectious Disease Diagnostics Market in Africa (2021-2030)
• Figure 30: Infectious Disease Diagnostics Market in South America (2021-2030)
• Figure 31: Market Drivers
• Figure 32: Market Barriers
• Figure 33: Marker Opportunities
• Figure 34: PORTER'S Five Force Analysis

Infectious disease diagnostic market by Type (Products [Instruments and Reagents & Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others), Technique (Polymerase chain reaction (PCR), Nucleic Acid Amplification Tests (NAAT), ELISA, Rapid immunochromatography assays, and Others), Application (Viral Diseases, Bacterial Diseases, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of infectious diseases and the rising product developmental activities worldwide

The infectious disease diagnostics market was valued at USD 38.52 billion in 2023 and is estimated to grow at a CAGR of 3.80% during the forecast period from 2024 to 2030 to reach USD 48.10 billion by 2030. The infectious disease diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B & C, and influenza, the introduction of new and innovative products by key players, and others that are acting as major factors contributing to the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

Infectious Disease Diagnostics Market Dynamics:

As per the World Health Organization (WHO) 2024, nearly 39 million people were living with HIV infection in 2022, globally. The source also stated that nearly 37.5 million were adults (aged 15 and above) and approximately 1.5 million people were children, aged less than 15 years. Infectious disease diagnostics are crucial in identifying HIV infection, enabling early detection, treatment monitoring, and preventing transmission. Techniques such as molecular testing, antigen/antibody assays, and point-of-care tests are widely used to diagnose HIV, assess viral load, and guide therapy decisions.

Data from the WHO 2024, stated that 304 million people were infected by hepatitis B and C across the world in the year 2022. The same source further stated that out of these 254 million were afflicted by hepatitis B and 50 million were affected by hepatitis C. Infectious disease diagnostics enable early detection and treatment of hepatitis B and C through techniques like serology, nucleic acid testing, and rapid diagnostics, helping to control and prevent transmission.

Additionally, the introduction of new and innovative products by market players are pushing forward the market share for same. For example, in February 2023, Thermo Fisher introduced real-time PCR kits in India for the detection of infectious diseases. The Applied Biosystems TaqPath PCR kits are designed to provide confidence and reliability in diagnostic development and testing for conditions like Multi-Drug Resistant Tuberculosis (MDR-TB), M. Tuberculosis complex (MTB), Hepatitis B (HBV), Hepatitis C (HCV), HIV, and for genetic analysis such as HLA-B27.

Hence, the interplay of all the above-mentioned factors is expected to drive the market for infectious disease diagnostics during the given forecast period from 2024 to 2030.

However, the risk of sample contamination during transport and storage, among other factors may prove to be challenging factors for the growth of the infectious disease diagnostics market.

Infectious Disease Diagnostics Market Segment Analysis:

Infectious disease diagnostic market by Type (Products [Instruments and Reagents & Kits] and Services), Technology (Genetic material based tests, Immunoassays, Microbial Cultures, and Others), Technique (Polymerase chain reaction (PCR), Nucleic Acid Amplification Tests (NAAT), ELISA, Rapid immunochromatography assays, and Others), Application (Viral Diseases, Bacterial Diseases, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment of the infectious disease diagnostics market, the immunoassays category is expected to have a significant revenue share in 2023. This is due to the various features and applications of immunoassays in diagnostics.

Immunoassay technology utilizes antibodies to identify and quantify pathogens, including viruses, bacteria, and other infectious agents. The key advantage of immunoassays is their sensitivity and specificity, which allow for the accurate detection of low levels of antigens or antibodies in patient samples. This is particularly valuable for early diagnosis and screening of diseases such as HIV, hepatitis, and influenza. Furthermore, immunoassays can be designed for high throughput, enabling the simultaneous testing of multiple samples, which is essential in outbreak situations. The technology also supports point-of-care testing, providing rapid results that facilitate timely clinical decision-making.

Additionally, in July 2023, Roche Diagnostics India announced the launch of the Elecsys(R) HCV Duo, India's first commercially available fully automated immunoassay. This assay enables the simultaneous and independent determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.

Therefore, the widespread uses of immunoassay in diagnostics, solidify the impact on the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall infectious disease diagnostics market:

Among all the regions, North America is estimated to hold a significant revenue share in the infectious disease diagnostics market. This domination is due to the growing burden of infectious diseases including tuberculosis, outbreaks of influenza, emerging pathogens, growing product developmental activities, presence of key manufacturers, among others that are expected to fuel the infectious disease diagnostics market in the region during forecast period from 2024 to 2030.

Public Health Agency of Canada (2024), stated that in 2022, there were 1,971 active tuberculosis cases in Canada. Infectious disease diagnostics is essential for the detection and identification of tuberculosis, utilizing techniques such as molecular testing, culture, and imaging. These methods facilitate prompt treatment, track disease transmission, and guide public health measures to manage outbreaks effectively.

Advancements in technology, such as the development of rapid diagnostic tests and molecular assays, enhance the accuracy and speed of diagnoses, making testing more accessible. The increase in point-of-care testing is also contributing to the market, allowing immediate results in clinical settings.

Rising product developmental activities by regulatory bodies in the region are likely to push forward the revenue shares for the same. For example, in November 2023, Abbott announced that it received the U.S. Food and Drug Administration (FDA) approval for its human papillomavirus or HPV screening solution.

Therefore, the interplay of all the factors mentioned above provide a conducive growth environment for the North America region in the infectious disease diagnostics market during the forecast period from 2024 to 2030.

Infectious Disease Diagnostics Market key players:

Some of the key market players operating in the infectious disease diagnostics market include BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Abbott, bioMerieux SA, QIAGEN, DiaSorin S.p.A, Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC., Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

Recent Developmental Activities in the Infectious Disease Diagnostics Market:

• In May 2024, Karius announced that its Karius Test, designed for diagnosing and managing lung infections in immunocompromised patients, received breakthrough device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
• In May 2022, BD announced the launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform in the US.
• In December 2021, Roche announced the launch of the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.

Key takeaways from the Infectious Disease Diagnostics Market Report study

• Market size analysis for current infectious disease diagnostics market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the infectious disease diagnostics market
• Various opportunities available for other competitors in the infectious disease diagnostics market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current infectious disease diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for infectious disease diagnostics market growth in the coming future?

Target audience who can be benefited from this infectious disease diagnostics market report study

• Infectious disease diagnostics providers
• Research organizations and consulting companies
• Infectious disease diagnostics related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in infectious disease diagnostics
• Various end-users who want to know more about the infectious disease diagnostics market and the latest developments in the infectious disease diagnostics market

Frequently Asked Questions for the Infectious Disease Diagnostics Market:

1. What are Infectious Disease Diagnostics?

The infectious disease diagnostics comprises of diagnostic tests, assays, instruments, and others that are utilized for the detection and identification of causative agents responsible for the disease.

2. What is the market for Infectious Disease Diagnostics?

The infectious disease diagnostics market was valued at USD 38.52 billion in 2023 and is estimated to grow at a CAGR of 3.80% during the forecast period from 2024 to 2030 to reach USD 48.10 billion by 2030.

3. What are the drivers for the Infectious Disease Diagnostics market?

The infectious disease diagnostics market is experiencing significant growth due to the increasing cases of infectious diseases including HIV, hepatitis B & C, influenza, introduction of new and innovative products by key players, and others that are acting as major factors contributing to the overall growth of the infectious disease diagnostics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Infectious Disease Diagnostics market?

Some of the major market players operating in the infectious disease diagnostics market include BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Abbott, bioMerieux SA, QIAGEN, DiaSorin S.p.A, Meridian Bioscience, Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Cepheid, Siemens Healthcare GmbH, Ortho Clinical Diagnostics, Biocare Medical, LLC., Bruker, Cardinal Health, Chembio Diagnostics, Inc., Novacyt, Trinity Biotech, OJ-Bio Limited, and others.

5. Which region has the highest share in the Infectious Disease Diagnostics market?

Among all the regions, North America is estimated to hold a significant revenue share in the infectious disease diagnostics market. This domination is due to the growing burden of infectious diseases including tuberculosis, outbreaks of influenza, emerging pathogens, growing product developmental activities, presence of key manufacturers, among others that are expected to fuel the infectious disease diagnostics market in the region during the forecast period from 2024 to 2030.

Table of Contents

1. Infectious Disease Diagnostics Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Infectious Disease Diagnostics Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Infectious Disease Diagnostics Market Key Factors Analysis

• 5.1. Infectious Disease Diagnostics Market Drivers
  • 5.1.1. Increasing cases of infectious diseases
  • 5.1.2. Rising product developmental activities
  • 5.1.3. Technological advancements in diagnostics
• 5.2. Infectious Disease Diagnostics Market Restraints and Challenges
  • 5.2.1. Risk of sample contamination during transport and storage
• 5.3. Infectious Disease Diagnostics Market Opportunities
  • 5.3.1. Integration of AI and ML associated with enhanced data interpretation
  • 5.3.2. Increasing availability and affordability of rapid diagnostic kits

6. Infectious Disease Diagnostics Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Infectious Disease Diagnostics Market Assessment

• 7.1. By Type
  • 7.1.1. Products
    • 7.1.1.1. Instruments
    • 7.1.1.2. Reagents and Kits
  • 7.1.2. Services
• 7.2. By Technology
  • 7.2.1. Genetic Material Based
  • 7.2.2. Immunoassays
  • 7.2.3. Microbial Cultures
  • 7.2.4. Others
• 7.3. By Technique
  • 7.3.1. Polymerase chain reaction (PCR)
  • 7.3.2. Nucleic Acid Amplification Tests (NAAT)
  • 7.3.3. ELISA
  • 7.3.4. Rapid immunochromatography assays
  • 7.3.5. Others
• 7.4. By Application
  • 7.4.1. Viral Diseases
  • 7.4.2. Bacterial Diseases
  • 7.4.3. Others
• 7.5. By End-User
  • 7.5.1. Hospitals
  • 7.5.2. Diagnostic Labs
  • 7.5.3. Others
• 7.6. By Geography
  • 7.6.1. North America
    • 7.6.1.1. United States Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.1.2. Canada Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.1.3. Mexico Infectious Disease Diagnostics Market Size in USD million (2021-2030)
  • 7.6.2. Europe
    • 7.6.2.1. France Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.2.2. Germany Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.2.3. United Kingdom Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.2.4. Italy Infectious Disease Diagnostics market size in USD million (2021-2030)
    • 7.6.2.5. Spain Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.2.6. Rest of Europe Infectious Disease Diagnostics Market Size in USD million (2021-2030)
  • 7.6.3. Asia-Pacific
    • 7.6.3.1. China Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.3.2. Japan Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.3.3. India Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.3.4. Australia Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.3.5. South Korea Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.3.6. Rest of Asia-Pacific Infectious Disease Diagnostics Market Size in USD million (2021-2030)
  • 7.6.4. Rest of the World (RoW)
    • 7.6.4.1. Middle East Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.4.2. Africa Infectious Disease Diagnostics Market Size in USD million (2021-2030)
    • 7.6.4.3. South America Infectious Disease Diagnostics Market Size in USD million (2021-2030)

8. Infectious Disease Diagnostics Market Company and Product Profiles

• 8.1. BD
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Bio-Rad Laboratories, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. F. Hoffmann-La Roche Ltd.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Abbott
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. bioMerieux SA
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. QIAGEN
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. DiaSorin S.p.A
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Meridian Bioscience, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Quest Diagnostics
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Thermo Fisher Scientific Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Cepheid
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Siemens Healthcare GmbH
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Ortho Clinical Diagnostics
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Biocare Medical, LLC.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Bruker
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Cardinal Health
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Chembio Diagnostics, Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Novacyt
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Trinity Biotech
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. OJ-Bio Limited
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us